Cargando…
High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604632/ https://www.ncbi.nlm.nih.gov/pubmed/33131259 http://dx.doi.org/10.3324/haematol.2019.235705 |
| _version_ | 1783604179734888448 |
|---|---|
| author | Mauro, Francesca R. Molica, Stefano Soddu, Stefano Ilariucci, Fiorella Coscia, Marta Zaja, Francesco Angelucci, Emanuele Re, Francesca Liberati, Anna Marina Tedeschi, Alessandra Reda, Gianluigi Pietrasanta, Daniela Gozzetti, Alessandro Battistini, Roberta Del Poeta, Giovanni Musolino, Caterina Nanni, Mauro Piciocchi, Alfonso Vignetti, Marco Neri, Antonino Albano, Francesco Cuneo, Antonio Del Giudice, Ilaria Starza, Irene Della De Propris, Maria Stefania Raponi, Sara Guarini, Anna R Foà, Robin |
| author_facet | Mauro, Francesca R. Molica, Stefano Soddu, Stefano Ilariucci, Fiorella Coscia, Marta Zaja, Francesco Angelucci, Emanuele Re, Francesca Liberati, Anna Marina Tedeschi, Alessandra Reda, Gianluigi Pietrasanta, Daniela Gozzetti, Alessandro Battistini, Roberta Del Poeta, Giovanni Musolino, Caterina Nanni, Mauro Piciocchi, Alfonso Vignetti, Marco Neri, Antonino Albano, Francesco Cuneo, Antonio Del Giudice, Ilaria Starza, Irene Della De Propris, Maria Stefania Raponi, Sara Guarini, Anna R Foà, Robin |
| author_sort | Mauro, Francesca R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7604632 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76046322020-11-06 High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) Mauro, Francesca R. Molica, Stefano Soddu, Stefano Ilariucci, Fiorella Coscia, Marta Zaja, Francesco Angelucci, Emanuele Re, Francesca Liberati, Anna Marina Tedeschi, Alessandra Reda, Gianluigi Pietrasanta, Daniela Gozzetti, Alessandro Battistini, Roberta Del Poeta, Giovanni Musolino, Caterina Nanni, Mauro Piciocchi, Alfonso Vignetti, Marco Neri, Antonino Albano, Francesco Cuneo, Antonio Del Giudice, Ilaria Starza, Irene Della De Propris, Maria Stefania Raponi, Sara Guarini, Anna R Foà, Robin Haematologica Letters to the Editor Fondazione Ferrata Storti 2020-01-30 /pmc/articles/PMC7604632/ /pubmed/33131259 http://dx.doi.org/10.3324/haematol.2019.235705 Text en Copyright© 2020 Ferrata Storti Foundation http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letters to the Editor Mauro, Francesca R. Molica, Stefano Soddu, Stefano Ilariucci, Fiorella Coscia, Marta Zaja, Francesco Angelucci, Emanuele Re, Francesca Liberati, Anna Marina Tedeschi, Alessandra Reda, Gianluigi Pietrasanta, Daniela Gozzetti, Alessandro Battistini, Roberta Del Poeta, Giovanni Musolino, Caterina Nanni, Mauro Piciocchi, Alfonso Vignetti, Marco Neri, Antonino Albano, Francesco Cuneo, Antonio Del Giudice, Ilaria Starza, Irene Della De Propris, Maria Stefania Raponi, Sara Guarini, Anna R Foà, Robin High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) |
| title | High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) |
| title_full | High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) |
| title_fullStr | High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) |
| title_full_unstemmed | High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) |
| title_short | High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) |
| title_sort | high rate of minimal residual disease responses in young and fit patients with ighv mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (fco2) |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604632/ https://www.ncbi.nlm.nih.gov/pubmed/33131259 http://dx.doi.org/10.3324/haematol.2019.235705 |
| work_keys_str_mv | AT maurofrancescar highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT molicastefano highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT soddustefano highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT ilariuccifiorella highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT cosciamarta highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT zajafrancesco highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT angelucciemanuele highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT refrancesca highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT liberatiannamarina highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT tedeschialessandra highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT redagianluigi highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT pietrasantadaniela highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT gozzettialessandro highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT battistiniroberta highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT delpoetagiovanni highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT musolinocaterina highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT nannimauro highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT piciocchialfonso highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT vignettimarco highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT neriantonino highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT albanofrancesco highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT cuneoantonio highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT delgiudiceilaria highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT starzairenedella highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT deproprismariastefania highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT raponisara highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT guariniannar highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 AT foarobin highrateofminimalresidualdiseaseresponsesinyoungandfitpatientswithighvmutatedchroniclymphocyticleukemiatreatedwithfrontlinefludarabinecyclophosphamideandintensifieddoseofofatumumabfco2 |